Skip to main content

Chan Zuckerberg Biohub starts handing out big bucks to disease researchers

chan zuckerberg biohub funds initiative
Chan Zuckerberg Initiative
When Mark Zuckerberg wonders about stuff, he wonders big. As befits someone who co-founded and now controls the world’s biggest social network, the Facebook CEO recently wondered if he could “help scientists to cure, prevent, or manage all diseases within our children’s lifetime.”

And not only has he been wondering about it — he’s actually trying to do it.

Recommended Videos

Zuckerberg and his wife, Priscilla Chan, the pair last September pledged $3 billion to fund medical research over the next decade. Distributed by the Chan Zuckerberg (CZ) Initiative, some of that money has just been released to the opening project — Biohub — a medical-focused research facility comprising “some of the best and brightest” scientists and engineers from Stanford University; the University of California, San Francisco; and the University of California, Berkeley, as well as an experienced engineering team linked to the CZ Initiative.

Each of the selected 47 investigators will receive up to $1.5 million over the next five years to conduct life science research in their respective areas of expertise. The work of the Biohub will focus on four main areas, namely new detection technologies, new treatments, new ways to prevent infection, and new approaches to rapid response when new threats emerge.

One of the first projects will be to further explore the types of cells that control the body’s organs, and ultimately to map every cell in the human body. Another goal is to design new tests and vaccines in an effort to overcome infectious diseases such as HIV, Ebola, and Zika.

“CZ Biohub investigators share our vision of a planet without disease,” said Joseph DeRisi, co-president of CZ Biohub and professor of biochemistry and biophysics at UC San Francisco. “To realize this vision, we are giving some of the world’s most creative and brilliant researchers access to groundbreaking technology and the freedom to pursue high-risk research.”

DeRisi added that CZ Biohub investigators aim to challenge “traditional thinking in pursuit of radical discoveries that will make even the most stubborn and deadly diseases treatable.”

Announcing the pledge last fall, Zuckerberg wrote in an online message, “Medicine has only been a modern science for about a century, and we’ve made incredible progress so far. Life expectancy has increased by one-fourth of a year per year since then, and if we only continue this trend, the average will reach 100 around the end of this century.”

The Zuck noted that as things stand, four types of illness — cancer, heart disease, infectious diseases, and neurological diseases — account for the majority of deaths, and suggested that meaningful progress could be made to “cure, prevent, or manage” these diseases using the right technology.

Over time, around $600 million of funding is expected to be received by the Biohub as its researchers attempt to solve the world’s biggest health problems.

Trevor Mogg
Contributing Editor
Not so many moons ago, Trevor moved from one tea-loving island nation that drives on the left (Britain) to another (Japan)…
Ford ships new NACS adapters to EV customers
Ford EVs at a Tesla Supercharger station.

Thanks to a Tesla-provided adapter, owners of Ford electric vehicles were among the first non-Tesla drivers to get access to the SuperCharger network in the U.S.

Yet, amid slowing supply from Tesla, Ford is now turning to Lectron, an EV accessories supplier, to provide these North American Charging Standard (NACS) adapters, according to InsideEVs.

Read more
Yamaha offers sales of 60% on e-bikes as it pulls out of U.S. market
Yamaha Pedal Assist ebikes

If you were looking for clues that the post-pandemic e-bike market reshuffle remains in full swing in the U.S., look no further than the latest move by Yamaha.

In a letter to its dealers, the giant Japanese conglomerate announced it will pull out of the e-bike business in the U.S. by the end of the year, according to Electrek.

Read more
Rivian offers $3,000 off select EVs to gasoline, hybrid vehicle drivers
Second-Gen Rivian R1S on a road

Early November typically kicks off the run-up to the Black Friday sales season, and this year, Rivian is betting it’s the perfect time to lure gasoline drivers toward its EVs.
If you own or lease a vehicle that runs on gasoline, which means even a hybrid vehicle, Rivian is ready to give you $3,000 off the purchase of one of its select fully electric vehicles -- no trade-in required.
The offer from the Irvine, California-based automaker extends to customers in the U.S. and Canada and runs through November 30, 2024. The program applies to Rivian 2025 R1S or R1T Dual Large, Dual Max, or Tri Max models purchased from R1 Shop.
Rivian’s new All-Electric Upgrade offer marks a change from a previous trade-in program that ran between April and June. There, owners of select 2018 gas-powered vehicles from Ford, Toyota, Jeep, Audi, and BMW could trade in their vehicle and receive up to $5,000 toward the purchase of a new Rivian.
This time, buyers of the R1S or R1T Rivian just need to provide proof of ownership or lease of a gas-powered or hybrid vehicle to receive the discount when they place their order.
Rivian is not going to be the only car maker offering discounts in November. Sluggish car sales from giants such as Stellantis and rising inventories of new cars due to improving supply chains suggest automakers and dealerships will be competing to offer big incentives through the year's end.
This follows several years of constrained supply following the COVID pandemic, which led to higher prices in North America.
According to CarEdge Insights, average selling prices for cars remain above what would be called affordable. But prices should continue improving along with rising inventories.
Stellantis brands are entering November with the most inventory, followed by GM and Ford, according to CarEdge. Toyota and Honda, meanwhile, have the least inventory, meaning they probably won’t be under pressure to offer big incentives.

Read more